BIOGEN INC. (BIIB) Factsheet
BIOGEN INC. (BIIB) Stock Analysis
Analysis from 10-Q filed 2025-10-30. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 5.7%. FCF margin 24.2%. D/E 0.0x. Source: 10-Q filed 2025-10-30.
| Metric | Value | Context |
|---|---|---|
| ROIC | 5.7% | Below expectations |
| FCF Margin | 24.2% | Strong cash generation |
| Debt/Equity | 0.0x | Conservative leverage |
ROIC 5.7% — Top 50% of sector peers. FCF margin 24.2% — Top 5%.
Explore BIOGEN INC.: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for BIIB: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: BIOGEN INC. earns 5.7% ROIC, Top 50% in Healthcare
ROIC TTM 5.7%, sector median -2.8%, Top 50%. DuPont: NOPAT margin 13.8% × asset turnover 0.3x. Gross margin 75.5%. Operating margin 16.3%. Source: 10-Q filed 2025-10-30.
| Metric | BIIB | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.7% | Warning | Above sector median of -2.8% |
| Return on Equity (ROE) | -1860.5% | Red flag | Moderate equity returns |
| Gross Margin | 75.5% | Excellent | Strong pricing power |
| Operating Margin | 16.3% | Good | Efficient operations |
Cash Flow: BIOGEN INC. generates $2.4B FCF at 24.2% margin, positive NaN/8 quarters
FCF TTM $2.4B. FCF margin 24.2%, Top 5%. OCF/Net income 1.9x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-30.
| Metric | BIIB | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 24.2% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $2.4B | Good | Positive cash generation |
| OCF/Net Income | 1.9x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: BIOGEN INC. at 0.0x leverage
Debt/Equity 0.0x. Source: 10-Q filed 2025-10-30.
| Metric | BIIB | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.0x | Excellent | Conservative capital structure |
Valuation: BIOGEN INC. trades at 20.1x earnings
P/E 20.1x. EV/Sales 2.6x. FCF yield 8.7%. Source: 10-Q filed 2025-10-30.
| Metric | BIIB | Rating | Context |
|---|---|---|---|
| P/E Ratio | 20.1x | Adequate | Premium valuation |
| EV/Sales | 2.6x | Good | Attractive revenue multiple |
| FCF Yield | 8.7% | Excellent | Attractive cash return |
Capital Allocation: BIOGEN INC. returns 0.0% shareholder yield
Total shareholder yield 0.0%. Capital returned $0 TTM. Source: 10-Q filed 2025-10-30.
| Metric | BIIB | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 0.0% | Warning | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $0 | Adequate | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.7% | Top 50% | - |
| Free Cash Flow Margin | 24.2% | Top 5% | - |
| Gross Margin | 75.5% | Top 50% | 1.2x above |
| Operating Margin | 16.3% | Top 25% | 7.2x above |
| Return on Equity (ROE) | -1860.5% | Top 5% | - |
| P/E Ratio | 20.1x | N/A | - |
Financial Scorecard
| Metric | BIIB | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.7% | Warning | Top 50% of sector (median: -2.8%) |
| Free Cash Flow Margin | 24.2% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 75.5% | Excellent | Top 50% of sector (median: 63.7%) |
| Debt to Equity Ratio | 0.0% | Excellent | Conservative capital structure |
| P/E Ratio (Price-to-Earnings) | 20.1x | Adequate | Fair value |
| Free Cash Flow Yield | 8.7% | Excellent | High cash return |
Frequently Asked Questions
Q: What is BIOGEN INC.'s Return on Invested Capital (ROIC)?
BIOGEN INC. (BIIB) has a trailing twelve-month Return on Invested Capital (ROIC) of 5.7%. Sector median -2.8%. Source: 10-Q filed 2025-10-30.
Q: What is BIOGEN INC.'s Free Cash Flow Margin?
BIOGEN INC. (BIIB) has a free cash flow margin of 24.2%, generating $2.4 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-30.
Q: What is BIOGEN INC.'s P/E ratio and how does it compare to peers?
BIOGEN INC. (BIIB) trades at a P/E ratio of 20.1x, which is above the sector median of N/A. EV/Sales 2.6x. FCF yield 8.7%. Source: 10-Q filed 2025-10-30.
Q: What is BIOGEN INC.'s revenue and earnings growth?
BIOGEN INC. (BIIB) grew revenue by 1.2% year-over-year. EPS -8.2% YoY. Source: 10-Q filed 2025-10-30.
Q: How does BIOGEN INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, BIOGEN INC. (BIIB) shows: ROIC 5.7%, sector median -2.8% (Top 50%). FCF margin 24.2%, sector median 0.0% (Top 5%). Gross margin 75.5%, 11.8pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with BIOGEN INC.?
Quantitative warning flags for BIOGEN INC. (BIIB): 1) ROIC declining -5.3% over 8 quarters. Source: 10-Q filed 2025-10-30.
Data Source: Data sourced from 10-Q filed 2025-10-30. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.